ASH: Venetoclax, Acalabrutinib Active in Relapsed CLL

Share this content:
ASH: Venetoclax, Acalabrutinib Active in Relapsed CLL
ASH: Venetoclax, Acalabrutinib Active in Relapsed CLL

TUESDAY, Dec. 8, 2015 (HealthDay News) -- Oral venetoclax and acalabrutinib are active in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), according to two studies published online Dec. 7 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the American Society of Hematology, held from Dec. 5 to 8 in Orlando, Fla.

Andrew W. Roberts, M.B., B.S., Ph.D., from the Royal Melbourne Hospital in Australia, and colleagues conducted a phase 1 dose-escalation study of daily oral venetoclax in patients with relapsed or refractory CLL or small lymphocytic lymphoma. Fifty-six patients received active treatment in one of eight dose groups in the dose-escalation phase and 60 additional patients were treated with stepwise ramp-up doses in an expansion cohort. The researchers found that venetoclax was active at all dose levels. Clinical tumor lysis syndrome occurred in three patients in the dose-escalation cohort, with one death, but did not occur in any patients in the expansion cohort.

John C. Byrd, M.D., from The Ohio State University in Columbus, and colleagues examined the safety and efficacy of acalabrutinib in patients with relapsed CLL. Patients were treated with acalabrutinib at a dose of 100 to 400 mg/day in a dose-escalation phase, and with 100 mg twice daily in the expansion phase. The researchers observed no dose-limiting toxic effects during the treatment period. Headache, diarrhea, and increased weight were the most common adverse events. The overall response rate was 95 percent at a median follow-up of 14.3 months.

"In this study the selective Bruton's tyrosine kinase inhibitor acalabrutinib had promising safety and efficacy profiles in patients with relapsed CLL," Byrd and colleagues write.

The Roberts study was funded by AbbVie and Genentech, the manufacturers of venetoclax. The Byrd study was partially funded by Acerta Pharma, the manufacturer of acalabrutinib.

Abstract - Roberts
Full Text
Abstract - Byrd
Full Text
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Some California Mosquitoes Can Carry Zika Virus

Some California Mosquitoes Can Carry Zika Virus

Aedes aegypti mosquitoes found to transmit Zika virus

Periodontal Inflammation a Risk With Tongue Piercing

Periodontal Inflammation a Risk With Tongue Piercing

And, two young females with tongue piercings have deep lingual infrabony lesions, periodontitis

Risk of OD Highest for First Days of Opioid  Benzodiazepine Use

Risk of OD Highest for First Days of ...

Five-fold increased risk of opioid-related overdose during first 90 days of concurrent use

is free, fast, and customized just for you!




Already a member?

Sign In Now »